Bayer, Orion to start Phase III trials for prostate cancer drug
pharmafile | June 3, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing |Â Â Bayer, drug trial, orion, prostate cancer, researchÂ
German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase III trial for the drug compound to treat prostate cancer.
The trial, which will start this year, will evaluate the safety and efficacy of the compound in combination with standard androgen deprivation therapy (ADT) and the chemotherapy docetaxel.
In 2014, Orion and Bayer entered into a global partnership for the compound, which was later expanded to include the joint development of the drug ODM-201 (BAY-1841788) for metastatic hormone-sensitive prostate cancer.
The trial drug is currently in Phase III study for high-risk non-metastatic castration-resistant prostate cancer.
Orion is eligible to receive milestone payments from Bayer upon achievement of certain ODM-201 related development, tech transfer and commercialization milestones, as well as substantial royalties on future sales. In addition, Orion will be responsible for manufacturing of the product.
Prostate cancer is the second most common form of cancer worldwide and the fifth leading cause of cancer-related death in men. More than 1.1 million men worldwide were diagnosed with the disease in 2012.
Anjali Shukla
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication …

Biocon Biologics gains EU approval for bone health therapies
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab …






